Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist)

Assets acting on this target.

Class
Dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist
Pathway
partial agonism at D3/D2 receptors stabilizes dopaminergic tone in mesolimbic/mesocortical pathways (lower functional response than full agonism but higher than antagonism); 5-HT1A partial agonism and 5-HT2A antagonism are proposed to contribute to effects on negative and mood symptoms

This mechanism targets dopamine D2 and D3 receptors, with a preference for the D3 subtype, using a partial agonist rather than a full blocker or activator. A partial agonist binds the receptor but produces a submaximal response, so it can either dampen excessive dopamine signaling or supply modest stimulation where dopamine tone is low, functioning as a stabilizer of dopaminergic activity rather than a simple on/off switch. This profile is combined with partial agonism at serotonin 5-HT1A receptors and antagonism at 5-HT2A (and related 5-HT2B) receptors, an activity pattern shared by several atypical antipsychotics that is thought to soften motor side effects and provide benefit for mood and negative symptoms alongside psychosis control. The rationale for emphasizing D3 selectivity is that this receptor subtype is concentrated in limbic brain regions linked to motivation, reward, and cognition, so preferential engagement there may address symptoms poorly served by older, D2-dominant antipsychotics. Such agents are studied broadly in schizophrenia and related psychotic and mood disorders, where restoring balanced dopaminergic and serotonergic signaling, rather than uniformly suppressing it, is the guiding therapeutic principle.

Related mechanisms

Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) drugs compared

2 drugs, stage by indication
2 drugs acting on Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Cariprazine (QLM1016)Qilu Pharmaceuticalsmall moleculePhase 3Phase 3 in Schizophrenia
ABBV-932AbbViesmall moleculePhase 1Not recorded

← all mechanisms